Simcere Reports Increased Growth In First Quarter Results, Eyes Future M&As
This article was originally published in PharmAsia News
You may also be interested in...
Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda
Continuing its acquisition strategy, Simcere Pharmaceutical Group, one of China's largest branded generics manufacturers, bought a 51 percent stake in Boda Pharmaceutical in a deal valued at $14.8 million (RMB 111 million), Simcere announced Sept. 28
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).